Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.
Melissa A Calton, Roxanne H Croze, Christian Burns...
https://pubmed.ncbi.nlm.nih.gov/39620832/Actively Recruiting
Led by 4D Molecular Therapeutics · Updated on 2026-08-21
215
Participants Needed
26
Research Sites
200 weeks
Total Duration
Researchers are evaluating 4D-150, an AAV-based gene therapy targeting VEGF-C and encoding aflibercept, in adults aged 50 and older with wet age-related macular degeneration AMD who are already receiving active anti-VEGF treatment. This Phase 12 trial includes dose escalation, randomized controlled masked expansion, and several substudies to assess safety, tolerability, and vector shedding. Participants will receive a single intravitreal injection of 4D-150 in the study eye. The trial includes Dose Escalation, Dose Expansion, Steroid Optimization, and Population Extension Cohorts. Some participants may also receive a one-time 4D-150 injection in the contralateral eye as part of a substudy. Aflibercept, a standard anti-VEGF drug, is given in a fixed regimen to control groups. Assessments occur monthly for 24 months, followed by a long-term follow-up up to 5 years to monitor safety and clinical activity. During the study, participants will have monthly evaluations including visual acuity tests using the ETDRS chart and retinal imaging by spectral domain optical coherence tomography SD-OCT. Researchers will track adverse events, need for additional aflibercept injections, and changes in retinal thickness and visual acuity. Safety and tolerability are monitored throughout the 52-week main period and during the extended follow-up. Some participants will also be involved in substudies focused on vector shedding and contralateral eye dosing, with regular safety assessments through week 52 and long-term monitoring through five years.
CONDITIONS
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
4
4DMT Patient Advocacy
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
4D Molecular Therapeutics
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | 4D‑150 gene therapy | Aflibercept injection (trial comparator) | Standard anti‑VEGF care |
|---|---|---|---|
| What it is | An investigational intravitreal gene therapy delivering dual transgenes targeting VEGF‑C and encoding aflibercept via an AAV vector | A commercially available intravitreal aflibercept injection used as the trial’s active comparator | Routine intravitreal anti‑VEGF injections such as aflibercept are standard treatment for neovascular AMD |
| Role in trial | Primary investigational therapy being tested across multiple dose cohorts | Active comparator to assess response against existing aflibercept therapy | Represents typical treatment outside the trial setting |
| Primary use | To provide sustained intra‑ocular expression of anti‑VEGF to reduce need for repeated injections | Suppresses neovascular activity by delivering aflibercept via intravitreal injection under standard dosing | Controls neovascular activity through regular intravitreal anti‑VEGF injections per guidelines |
| How it is given or performed | Single intravitreal injection of AAV‑based 4D‑150 gene therapy with monitoring across dose cohorts | Intravitreal injection of aflibercept as per trial schedule | Intravitreal injections of anti‑VEGF at intervals determined clinically |
| Evidence status | Efficacy and safety under investigation; data not yet available | Well‑established efficacy in maintaining or improving vision in nAMD | Strong evidence supports anti‑VEGF injections as effective first‑line treatment |
| Important risks | Unknown safety profile; risks of gene therapy and vector shedding under study | Known injection‑related and anti‑VEGF risks (e.g. endophthalmitis, intraocular inflammation) established in clinical use | Well‑characterized safety profile used routinely |
| Important limitations | Long‑term durability, immune response, and optimal dose unknown | Requires repeated intravitreal injections over time, imposing treatment burden | Frequent injections and monitoring may impact adherence and outcomes |
| Patient impact | Potential to reduce need for frequent injections if durable effect achieved, but impact not yet known | Helps maintain or improve vision, but requires ongoing injection visits | Proven to preserve vision with established schedules, but frequent visits may affect quality of life |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 24 months
Participants receive a single intravitreal injection of 4D-150 gene therapy or fixed regimen aflibercept as assigned.
Monthly visits
Duration - Up to 5 years
Participants who received 4D-150 enter long-term follow-up to monitor safety and clinical activity up to 5 years after treatment.
Regular assessments during follow-up
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
10
Have more questions? Get in touch with our team for quick support
Melissa A Calton, Roxanne H Croze, Christian Burns...
https://pubmed.ncbi.nlm.nih.gov/39620832/4D Molecular Therapeutics
Lead Sponsor